- Home
- IOBT vs AVTX Comparison
IOBT vs AVTX Comparison
Compare IOBT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOBT | AVTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 248.3M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IOBT | AVTX |
|---|---|---|
| Price | $0.70 | $19.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $3.50 | ★ $32.29 |
| AVG Volume (30 Days) | ★ 805.8K | 341.4K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.32 | $3.39 |
| 52 Week High | $2.79 | $20.72 |
Technical Indicators
Market Signals| Indicator | IOBT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 56.25 |
| Support Level | $0.61 | $18.58 |
| Resistance Level | $0.72 | $20.20 |
| Average True Range (ATR) | 0.07 | 1.60 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 35.54 | 69.75 |
Price Performance
Historical ComparisonAbout IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).